Benzinga | Jun 21, 2021 11:21AM EDT

Kymera Therapeutics' KT-413 Shows Encouraging Preclinical Anti-Cancer Activity

* Kymera Therapeutics Inc (NASDAQ:KYMR) has announced new preclinical data on its IRAKIMiD degrader KT-413's potential as both a monotherapy and in combination with other anticancer agents.

* The data were featured at the Annual International Conference on Malignant Lymphoma (ICML) virtual meeting.

* KT-413 is currently in preclinical development, and Kymera plans to submit an Investigational New Drug Application to the FDA in the second half of 2021.

* In the mouse xenograft model, intermittent dosing of KT-413 in vivo induced deep and sustained antitumor activity, including complete or partial regressions.

* The response was found to be superior to the clinically active IRAK4 kinase inhibitor Curis Inc's (NASDAQ:CRIS) CA-4948 or the latest generation IMiD CC-220 from Bristol Myers' (NYSE:BMS) Celgene.

* KT-413 showed potent tumor growth inhibition (87%-100%) in multiple MYD88-mutant diffuse large B-cell lymphoma patient-derived xenograft in vivo models.

* The data also demonstrated KT-413's supra-additive activity in combination with rituximab, BTK inhibitors, and BCL2 inhibitors, supporting the clinical potential for KT-413 as a combination therapy in MYD88-mutant DLBCL and other MYD88-mutant B cell lymphomas.

* Price Action: KYMR shares are up 0.72% at $47.69 on the last check Monday.